[go: up one dir, main page]

IL122212A - Rapamycin derivatives, pharmaceutical compositions comprising them and their preparation - Google Patents

Rapamycin derivatives, pharmaceutical compositions comprising them and their preparation

Info

Publication number
IL122212A
IL122212A IL12221296A IL12221296A IL122212A IL 122212 A IL122212 A IL 122212A IL 12221296 A IL12221296 A IL 12221296A IL 12221296 A IL12221296 A IL 12221296A IL 122212 A IL122212 A IL 122212A
Authority
IL
Israel
Prior art keywords
preparation
pharmaceutical compositions
rapamycin derivatives
rapamycin
derivatives
Prior art date
Application number
IL12221296A
Other languages
English (en)
Other versions
IL122212A0 (en
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9511704.0A external-priority patent/GB9511704D0/en
Priority claimed from GBGB9513754.3A external-priority patent/GB9513754D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL122212A0 publication Critical patent/IL122212A0/xx
Publication of IL122212A publication Critical patent/IL122212A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
IL12221296A 1995-06-09 1996-06-05 Rapamycin derivatives, pharmaceutical compositions comprising them and their preparation IL122212A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9511704.0A GB9511704D0 (en) 1995-06-09 1995-06-09 Organic compounds
GBGB9513754.3A GB9513754D0 (en) 1995-07-06 1995-07-06 Organic compounds
PCT/EP1996/002441 WO1996041807A1 (en) 1995-06-09 1996-06-05 Rapamycin derivatives

Publications (2)

Publication Number Publication Date
IL122212A0 IL122212A0 (en) 1998-04-05
IL122212A true IL122212A (en) 2001-08-26

Family

ID=26307190

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12221296A IL122212A (en) 1995-06-09 1996-06-05 Rapamycin derivatives, pharmaceutical compositions comprising them and their preparation

Country Status (30)

Country Link
US (2) US5985890A (xx)
EP (1) EP0833828B1 (xx)
JP (1) JP3226545B2 (xx)
KR (1) KR100400620B1 (xx)
CN (1) CN1124276C (xx)
AR (1) AR003426A1 (xx)
AT (1) ATE228135T1 (xx)
AU (1) AU712193B2 (xx)
BR (1) BR9609260A (xx)
CA (1) CA2219659C (xx)
CO (1) CO4440629A1 (xx)
CZ (1) CZ292233B6 (xx)
DE (1) DE69624921T2 (xx)
DK (1) DK0833828T3 (xx)
ES (1) ES2187660T3 (xx)
FI (1) FI113051B (xx)
HK (1) HK1014949A1 (xx)
HU (1) HU228234B1 (xx)
IL (1) IL122212A (xx)
MY (1) MY145291A (xx)
NO (1) NO317058B1 (xx)
NZ (1) NZ311647A (xx)
PE (1) PE4598A1 (xx)
PL (1) PL184731B1 (xx)
PT (1) PT833828E (xx)
RU (1) RU2158267C2 (xx)
SK (1) SK284529B6 (xx)
TR (1) TR199701567T1 (xx)
TW (1) TW410226B (xx)
WO (1) WO1996041807A1 (xx)

Families Citing this family (244)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7279561B1 (en) * 1993-04-23 2007-10-09 Wyeth Anti-rapamycin monoclonal antibodies
DE69435044T2 (de) 1993-04-23 2008-09-18 Wyeth Rapamycin - Konjugate und Antikörper
US6187757B1 (en) 1995-06-07 2001-02-13 Ariad Pharmaceuticals, Inc. Regulation of biological events using novel compounds
BE1009856A5 (fr) 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
GB9606452D0 (en) * 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
US6258823B1 (en) * 1996-07-12 2001-07-10 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
US20050031611A1 (en) * 1998-05-08 2005-02-10 Beth Israel Deaconess Medical Center Transplant tolerance by costimulation blockade and T-cell activation-induced apoptosis
GB9826882D0 (en) * 1998-12-07 1999-01-27 Novartis Ag Organic compounds
IL144144A0 (en) 1999-01-13 2002-05-23 Bayer Ag Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US6955661B1 (en) * 1999-01-25 2005-10-18 Atrium Medical Corporation Expandable fluoropolymer device for delivery of therapeutic agents and method of making
US6331547B1 (en) 1999-08-18 2001-12-18 American Home Products Corporation Water soluble SDZ RAD esters
US7067526B1 (en) 1999-08-24 2006-06-27 Ariad Gene Therapeutics, Inc. 28-epirapalogs
WO2001014387A1 (en) 1999-08-24 2001-03-01 Ariad Gene Therapeutics, Inc. 28-epirapalogs
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US6790228B2 (en) 1999-12-23 2004-09-14 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US7807211B2 (en) 1999-09-03 2010-10-05 Advanced Cardiovascular Systems, Inc. Thermal treatment of an implantable medical device
US6277983B1 (en) 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
US6670355B2 (en) * 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
US6399626B1 (en) * 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
US20040018228A1 (en) * 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
US20040241211A9 (en) * 2000-11-06 2004-12-02 Fischell Robert E. Devices and methods for reducing scar tissue formation
US6534693B2 (en) 2000-11-06 2003-03-18 Afmedica, Inc. Surgically implanted devices having reduced scar tissue formation
JP2004526425A (ja) 2000-11-28 2004-09-02 ワイス 前立腺癌の診断および治療に有用なｆｋｂｐ核酸およびポリペプチドの発現分析
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
AU2005201004A1 (en) * 2001-02-19 2005-03-24 Novartis Ag Cancer treatment
AU2016206379B2 (en) * 2001-02-19 2017-09-14 Novartis Ag Cancer Treatment
EP2764865A3 (en) 2001-02-19 2014-10-01 Novartis AG Cancer treatment
AU2011226835C1 (en) * 2001-02-19 2018-01-04 Novartis Ag Cancer treatment
MXPA03011095A (es) * 2001-05-29 2005-04-28 Guilford Pharm Inc Metodo para tratar una lesion nerviosa causada por cirugia.
DK1285659T3 (da) * 2001-08-13 2007-10-29 Fond Salvatore Maugeri Clinica Anvendelse af clarithromycin til fremstilling af et lægemiddel til behandlingen af arthritis deformans
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
BR0307544A (pt) * 2002-02-01 2004-12-07 Ariad Gene Therapeutics Inc Compostos contendo fósforos, componentes e composição bem como, sua utilização através de métodos de tratamentos
AU2003209116A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
EP1340498A1 (en) * 2002-03-01 2003-09-03 Schering Aktiengesellschaft Use of epothilones in the treatment of brain diseases associated with proliferative processes
BR0311173A (pt) 2002-05-16 2005-03-15 Novartis Ag Uso de agentes de ligação do receptor de edg em câncer
JP4265888B2 (ja) * 2002-06-12 2009-05-20 株式会社リコー 画像形成装置
EP1655372A3 (en) 2002-07-16 2008-01-16 Biotica Technology Limited Production of polyketides and other natural products
EP2255798B1 (en) 2002-09-24 2014-12-24 Novartis AG FTY720 for use in the treatment of optic neuritis
AU2003293529A1 (en) 2002-12-16 2004-07-29 Nitromed, Inc. Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
US20040225077A1 (en) 2002-12-30 2004-11-11 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US20070155771A1 (en) * 2003-04-11 2007-07-05 David Rubinsztein Methods and means for treating protein conformational disorders
US7160867B2 (en) 2003-05-16 2007-01-09 Isotechnika, Inc. Rapamycin carbohydrate derivatives
PL1626714T3 (pl) 2003-05-20 2007-12-31 Bayer Healthcare Llc Diarylowe pochodne mocznika do schorzeń, w których pośredniczy PDGFR
JP4351474B2 (ja) * 2003-06-05 2009-10-28 住友金属工業株式会社 ゴルフクラブヘッドフェース用板材の製造方法およびゴルフクラブヘッド
JP4041774B2 (ja) * 2003-06-05 2008-01-30 住友金属工業株式会社 β型チタン合金材の製造方法
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
US8021331B2 (en) * 2003-09-15 2011-09-20 Atrium Medical Corporation Method of coating a folded medical device
CA2544731A1 (en) 2003-11-03 2005-05-12 Altachem Pharma Ltd. Rapamycin peptides conjugates: synthesis and uses thereof
US7220755B2 (en) * 2003-11-12 2007-05-22 Biosensors International Group, Ltd. 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
GB0327840D0 (en) * 2003-12-01 2003-12-31 Novartis Ag Organic compounds
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
GB0417852D0 (en) 2004-08-11 2004-09-15 Biotica Tech Ltd Production of polyketides and other natural products
US9012506B2 (en) 2004-09-28 2015-04-21 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
WO2006036984A2 (en) 2004-09-28 2006-04-06 Atrium Medical Corporation Stand-alone film and methods for making the same
US9000040B2 (en) 2004-09-28 2015-04-07 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US8021849B2 (en) * 2004-11-05 2011-09-20 Siemens Healthcare Diagnostics Inc. Methods and kits for the determination of sirolimus in a sample
WO2006053754A1 (en) * 2004-11-19 2006-05-26 Novartis Ag COMBINATIONS OF ANTI-ATHEROSCLEROTIC PEPTIDES AND AN mTOR INHIBITING AGENT AND THEIR METHODS OF USE
GB0504544D0 (en) 2005-03-04 2005-04-13 Novartis Ag Organic compounds
WO2006095173A2 (en) 2005-03-11 2006-09-14 Biotica Technology Limited Medical uses of 39-desmethoxyrapamycin and analogues thereof
GB0504994D0 (en) 2005-03-11 2005-04-20 Biotica Tech Ltd Novel compounds
US7189582B2 (en) * 2005-04-27 2007-03-13 Dade Behring Inc. Compositions and methods for detection of sirolimus
WO2006128660A1 (en) * 2005-05-31 2006-12-07 Novartis Ag Combination of hmg-coa reductase inhibitors amd mtor inhibitors
ES2691646T3 (es) 2005-07-15 2018-11-28 Micell Technologies, Inc. Revestimientos poliméricos que contienen polvo de fármaco de morfología controlada
WO2007011708A2 (en) 2005-07-15 2007-01-25 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
US20080200486A1 (en) 2005-07-20 2008-08-21 Heidi Lane Combination Of Organic Compounds
EP1912675B1 (en) 2005-07-25 2014-02-12 Emergent Product Development Seattle, LLC B-cell reduction using cd37-specific and cd20-specific binding molecules
AU2006284922B2 (en) 2005-08-30 2012-01-19 University Of Miami Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists and immunotoxins
US9278161B2 (en) 2005-09-28 2016-03-08 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
US9427423B2 (en) 2009-03-10 2016-08-30 Atrium Medical Corporation Fatty-acid based particles
US20070134739A1 (en) * 2005-12-12 2007-06-14 Gyros Patent Ab Microfluidic assays and microfluidic devices
GB0601406D0 (en) * 2006-01-24 2006-03-08 Novartis Ag Organic Compounds
RU2473343C2 (ru) * 2006-02-02 2013-01-27 Новартис Аг Лечение туберозного склероза
WO2007127363A2 (en) 2006-04-26 2007-11-08 Micell Technologies, Inc. Coatings containing multiple drugs
AU2007287809A1 (en) * 2006-08-22 2008-02-28 Novartis Ag Rapamycin and its derivatives for the treatment of liver-associated fibrosing disorders
US8088789B2 (en) 2006-09-13 2012-01-03 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
US10695327B2 (en) 2006-09-13 2020-06-30 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
JP6049160B2 (ja) 2006-09-13 2016-12-27 エリクシアー メディカル コーポレイション 大環状ラクトン化合物およびその使用方法
JP5456321B2 (ja) 2006-11-27 2014-03-26 テルモ株式会社 Ｏ−アルキル化ラパマイシン誘導体の製造方法およびｏ−アルキル化ラパマイシン誘導体
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
WO2008086369A1 (en) 2007-01-08 2008-07-17 Micell Technologies, Inc. Stents having biodegradable layers
US7938286B2 (en) * 2007-02-13 2011-05-10 Gateway Plastics, Inc. Container system
US8921642B2 (en) 2008-01-11 2014-12-30 Massachusetts Eye And Ear Infirmary Conditional-stop dimerizable caspase transgenic animals
US20100048524A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
US20090253733A1 (en) * 2008-04-02 2009-10-08 Biointeractions, Ltd. Rapamycin carbonate esters
PT2132228E (pt) 2008-04-11 2011-10-11 Emergent Product Dev Seattle Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
CN102083397B (zh) 2008-04-17 2013-12-25 米歇尔技术公司 具有生物可吸收层的支架
KR20170081755A (ko) 2008-06-20 2017-07-12 노파르티스 아게 다발성 경화증을 치료하기 위한 소아용 조성물
WO2011009096A1 (en) 2009-07-16 2011-01-20 Micell Technologies, Inc. Drug delivery medical device
US9486431B2 (en) 2008-07-17 2016-11-08 Micell Technologies, Inc. Drug delivery medical device
KR20110074758A (ko) * 2008-10-03 2011-07-01 엘릭서 메디컬 코포레이션 마크로사이클릭 락톤 화합물 및 이를 사용하는 방법
CN102292078A (zh) 2008-11-11 2011-12-21 得克萨斯大学体系董事会 哺乳动物雷帕霉素靶蛋白的抑制
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
ES2552087T3 (es) 2009-02-05 2015-11-25 Tokai Pharmaceuticals, Inc. Nuevos profármacos de inhibidores de CYP17 esteroidales/antiandrógenos
CN102481195B (zh) 2009-04-01 2015-03-25 米歇尔技术公司 涂覆支架
EP3366326A1 (en) 2009-04-17 2018-08-29 Micell Technologies, Inc. Stents having controlled elution
SG178125A1 (en) 2009-08-03 2012-03-29 Univ Miami Method for in vivo expansion of t regulatory cells
US20110038910A1 (en) 2009-08-11 2011-02-17 Atrium Medical Corporation Anti-infective antimicrobial-containing biomaterials
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
US20170079962A1 (en) 2009-11-11 2017-03-23 Rapamycin Holdings, Llc Oral Rapamycin Preparation and Use for Stomatitus
WO2011097103A1 (en) 2010-02-02 2011-08-11 Micell Technologies, Inc. Stent and stent delivery system with improved deliverability
MX2012011912A (es) 2010-04-13 2012-11-16 Novartis Ag Combinacion que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclia (cdk4/6) y un inhibidor de mtor para tratar cancer.
MX2012012058A (es) 2010-04-16 2012-11-22 Novartis Ag Combinacion de compuestos organicos.
EP2560576B1 (en) 2010-04-22 2018-07-18 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
JP6042801B2 (ja) 2010-04-27 2016-12-14 ロシュ グリクアート アーゲー ｍＴＯＲインヒビターとのアフコシル化ＣＤ２０抗体の併用療法
CA2805631C (en) 2010-07-16 2018-07-31 Micell Technologies, Inc. Drug delivery medical device
WO2012009707A2 (en) 2010-07-16 2012-01-19 Atrium Medical Corporation Composition and methods for altering the rate of hydrolysis of cured oil-based materials
WO2012112847A1 (en) 2011-02-18 2012-08-23 Novartis Pharma Ag mTOR/JAK INHIBITOR COMBINATION THERAPY
BR112013027486A2 (pt) 2011-04-25 2017-02-14 Novartis Ag combinação de um inibidor de fosfatidilinositol-3-cinase (pi3k) e um inibidor de mtor
EP2702173A1 (en) 2011-04-25 2014-03-05 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
CA2841360A1 (en) 2011-07-15 2013-01-24 Micell Technologies, Inc. Drug delivery medical device
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
EP2589383A1 (en) 2011-11-06 2013-05-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin FKBP subtype-specific rapamycin analogue for use in treatment of diseases
CN103945850A (zh) 2011-11-15 2014-07-23 诺华股份有限公司 磷酸肌醇-3-激酶抑制剂与Janus激酶2-信号转导和转录激活因子5通路的调节剂的组合
GB201122305D0 (en) 2011-12-23 2012-02-01 Biotica Tech Ltd Novel compound
US9867880B2 (en) 2012-06-13 2018-01-16 Atrium Medical Corporation Cured oil-hydrogel biomaterial compositions for controlled drug delivery
WO2013192367A1 (en) 2012-06-22 2013-12-27 Novartis Ag Neuroendocrine tumor treatment
EP2869818A1 (en) 2012-07-06 2015-05-13 Novartis AG Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction
US20150290176A1 (en) 2012-10-12 2015-10-15 The Board Of Regents Of The University Of Texas System Use of mtor inhibitors to treat vascular cognitive impairment
EP2919759A4 (en) 2012-11-14 2016-07-20 Ohio State Innovation Foundation MATERIALS AND METHODS FOR THE TREATMENT OF GLIOBLASTOMES
EP2943253B1 (en) 2013-01-09 2021-10-20 University Of Miami Compositions and methods for the regulation of t regulatory cells using tl1a-ig fusion protein and il-2
CA2905419C (en) 2013-03-12 2020-04-28 Micell Technologies, Inc. Bioabsorbable biomedical implants
DK2968281T3 (da) 2013-03-13 2020-11-02 Univ Texas Mtor-hæmmere til forebyggelse af vækst af tarmpolyp
MX2015012274A (es) 2013-03-14 2016-06-02 Univ Maryland Agentes de sub-regulacion del receptor de androgeno y uso de los mismos.
EP2994758B1 (en) 2013-05-08 2017-12-20 Opthea Limited Biomarkers for age-related macular degeneration (amd)
EP2996629B1 (en) 2013-05-15 2021-09-22 Micell Technologies, Inc. Bioabsorbable biomedical implants
WO2014200659A1 (en) 2013-06-11 2014-12-18 Clontech Laboratories, Inc. Protein enriched microvesicles and methods of making and using the same
AU2014282831B2 (en) * 2013-06-20 2016-12-01 Novartis Ag Alkylation with an alkyl fluoroalkyl sulfonate
BR112016002970A2 (pt) 2013-08-12 2017-09-12 Tokai Pharmaceuticals Inc biomarcadores para o tratamento de distúrbios neoplásicos que usa terapias direcionadas ao androgênio
US9580758B2 (en) 2013-11-12 2017-02-28 Luc Montagnier System and method for the detection and treatment of infection by a microbial agent associated with HIV infection
TWI679976B (zh) 2013-11-13 2019-12-21 瑞士商諾華公司 低及免疫增強劑量之ｍｔｏｒ抑制劑及其用途
CA3225456A1 (en) 2013-12-19 2015-06-25 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
EP3087101B1 (en) 2013-12-20 2024-06-05 Novartis AG Regulatable chimeric antigen receptor
CN103739616B (zh) * 2013-12-27 2015-12-30 福建省微生物研究所 含噻唑基雷帕霉素类衍生物及其应用
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
CA2933908C (en) 2013-12-31 2024-01-30 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
MX2016010482A (es) 2014-02-11 2016-10-17 Novartis Ag Combinaciones farmaceuticas que comprenden un inhibidor de pi3k para el tratamiento de cancer.
EP3119425B1 (en) 2014-03-15 2020-09-23 Novartis AG Regulatable chimeric antigen receptor
CN106163547A (zh) 2014-03-15 2016-11-23 诺华股份有限公司 使用嵌合抗原受体治疗癌症
CA2943609A1 (en) 2014-03-27 2015-10-01 The Brigham And Women's Hospital, Inc. Metabolically-activated drug conjugates to overcome resistance in cancer therapy
AU2015244039B2 (en) 2014-04-07 2021-10-21 Novartis Ag Treatment of cancer using anti-CD19 chimeric antigen receptor
WO2015171723A1 (en) 2014-05-06 2015-11-12 Research Development Foundation Methods for treating insulin resistance and for sensitizing patients to glp1 agonist therapy
CN106659758A (zh) 2014-06-02 2017-05-10 儿童医疗中心有限公司 用于免疫调节的组合物和方法
RU2747384C2 (ru) 2014-07-21 2021-05-04 Новартис Аг Лечение рака с помощью химерного антигенного рецептора к cd33
WO2016014530A1 (en) 2014-07-21 2016-01-28 Novartis Ag Combinations of low, immune enhancing. doses of mtor inhibitors and cars
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
ES2781175T3 (es) 2014-07-31 2020-08-31 Novartis Ag Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico
CA2958200A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using a gfr alpha-4 chimeric antigen receptor
TWI719946B (zh) 2014-08-19 2021-03-01 瑞士商諾華公司 使用ｃｄ１２３嵌合抗原受體治療癌症
CN113620978A (zh) 2014-09-11 2021-11-09 加利福尼亚大学董事会 mTORC1抑制剂
JP6839074B2 (ja) 2014-09-17 2021-03-03 ノバルティス アーゲー 養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング
IL279420B2 (en) 2014-10-08 2024-09-01 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
WO2016066608A1 (en) 2014-10-28 2016-05-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary cell senescence and peripheral aging
WO2016164580A1 (en) 2015-04-07 2016-10-13 Novartis Ag Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
US11896614B2 (en) 2015-04-17 2024-02-13 Novartis Ag Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
EA201792314A1 (ru) 2015-05-20 2018-05-31 Новартис Аг Фармацевтическая комбинация эверолимуса и дактолисиба
JP2018537447A (ja) 2015-11-11 2018-12-20 ノバルティス アーゲー ミオスタチンアンタゴニストの使用、それを含有する組合せ物およびその使用
EP4014967A1 (en) 2016-04-29 2022-06-22 Icahn School of Medicine at Mount Sinai Targeting the innate immunesystem to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis
WO2018017708A1 (en) 2016-07-20 2018-01-25 University Of Utah Research Foundation Cd229 car t cells and methods of use thereof
KR20240153612A (ko) 2016-10-07 2024-10-23 노파르티스 아게 암의 치료를 위한 키메라 항원 수용체
TW201825090A (zh) 2016-11-23 2018-07-16 瑞士商諾華公司 增強免疫反應之方法
WO2018100190A1 (en) 2016-12-02 2018-06-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for diagnosing renal cell carcinoma
PT3558955T (pt) 2016-12-22 2021-10-19 Amgen Inc Derivados de benzisotiazol, isotiazolo[3,4-b]piridina, quinazolina, ftalazina, pirido[2,3-d]piridazima e pirido[2,3-d]pirimidina como inibidores de kras g12c para tratamento de cancro de pulmão, pancreático ou colorretal
CN110603038A (zh) 2017-02-10 2019-12-20 塔姆山治疗公司 雷帕霉素类似物
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3848065B1 (en) 2017-05-15 2023-07-26 C. R. Bard, Inc. Medical device with drug-eluting coating and intermediate layer
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
EP3679040B1 (en) 2017-09-08 2022-08-03 Amgen Inc. Inhibitors of kras g12c and methods of using the same
UY37900A (es) 2017-09-26 2019-04-30 Novartis Ag Nuevos derivados de rapamicina
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
US20210047405A1 (en) 2018-04-27 2021-02-18 Novartis Ag Car t cell therapies with enhanced efficacy
US20210396739A1 (en) 2018-05-01 2021-12-23 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
MX2020011564A (es) 2018-05-01 2021-01-29 Revolution Medicines Inc Analogos de rapamicina unidos a c26 como inhibidores de mtor.
LT3788049T (lt) 2018-05-01 2023-07-25 Revolution Medicines, Inc. Rapamicino analogai, sujungti su c40-, c28- ir c32-, kaip mtor inhibitoriai
MX2020010836A (es) 2018-05-04 2021-01-08 Amgen Inc Inhibidores de kras g12c y métodos para su uso.
CA3099118A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
MA52564A (fr) 2018-05-10 2021-03-17 Amgen Inc Inhibiteurs de kras g12c pour le traitement du cancer
AU2019278998B2 (en) 2018-06-01 2023-11-09 Amgen Inc. KRAS G12C inhibitors and methods of using the same
MX2020012204A (es) 2018-06-11 2021-03-31 Amgen Inc Inhibidores de kras g12c para tratar el cáncer.
WO2020050890A2 (en) 2018-06-12 2020-03-12 Amgen Inc. Kras g12c inhibitors and methods of using the same
CA3103282A1 (en) 2018-06-15 2019-12-19 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
WO2020101675A1 (en) 2018-11-14 2020-05-22 Lutonix, Inc. Medical device with drug-eluting coating on modified device surface
JP7516029B2 (ja) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
MX2021005700A (es) 2018-11-19 2021-07-07 Amgen Inc Inhibidores de kras g12c y metodos de uso de los mismos.
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
ES2997190T3 (en) 2018-12-20 2025-02-14 Amgen Inc Heteroaryl amides useful as kif18a inhibitors
EP3897852A1 (en) 2018-12-20 2021-10-27 Amgen Inc. Kif18a inhibitors
MA54546A (fr) 2018-12-20 2022-03-30 Amgen Inc Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
MX2021007104A (es) 2018-12-20 2021-08-11 Amgen Inc Inhibidores de kif18a.
JP2022522778A (ja) 2019-03-01 2022-04-20 レボリューション メディシンズ インコーポレイテッド 二環式ヘテロシクリル化合物及びその使用
US20230148450A9 (en) 2019-03-01 2023-05-11 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
CN113939324A (zh) 2019-04-08 2022-01-14 巴德外周血管股份有限公司 在经改性装置表面上具有药物洗脱涂层的医疗装置
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
MX2021014126A (es) 2019-05-21 2022-01-04 Amgen Inc Formas en estado solido.
JP2021008453A (ja) 2019-07-02 2021-01-28 エフェクター・セラピューティクス，インコーポレーテッド 翻訳阻害剤およびその使用
CA3146693A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
MX2022001181A (es) 2019-08-02 2022-02-22 Amgen Inc Inhibidores de kif18a.
WO2021026099A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
EP4007638A1 (en) 2019-08-02 2022-06-08 Amgen Inc. Pyridine derivatives as kif18a inhibitors
WO2021041348A1 (en) 2019-08-26 2021-03-04 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
US20220402916A1 (en) 2019-09-18 2022-12-22 Merck Sharp & Dohme Corp. Small molecule inhibitors of kras g12c mutant
CA3155857A1 (en) 2019-10-24 2021-04-29 Amgen Inc. Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
US11697657B2 (en) 2019-10-28 2023-07-11 Merck Sharp & Dohme Llc Small molecule inhibitors of KRAS G12C mutant
WO2021085653A1 (en) 2019-10-31 2021-05-06 Taiho Pharmaceutical Co., Ltd. 4-aminobut-2-enamide derivatives and salts thereof
TW202132316A (zh) 2019-11-04 2021-09-01 美商銳新醫藥公司 Ｒａｓ抑制劑
JP2022553859A (ja) 2019-11-04 2022-12-26 レボリューション メディシンズ インコーポレイテッド Ｒａｓ阻害剤
CN114901366A (zh) 2019-11-04 2022-08-12 锐新医药公司 Ras抑制剂
PE20230249A1 (es) 2019-11-08 2023-02-07 Revolution Medicines Inc Compuestos de heteroarilo biciclicos y usos de estos
US20230192682A1 (en) 2019-11-14 2023-06-22 Amgen Inc. Improved synthesis of kras g12c inhibitor compound
CN114728960A (zh) 2019-11-14 2022-07-08 美国安进公司 Kras g12c抑制剂化合物的改善的合成
JP2023505100A (ja) 2019-11-27 2023-02-08 レボリューション メディシンズ インコーポレイテッド 共有ｒａｓ阻害剤及びその使用
WO2021106231A1 (en) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
CA3163680A1 (en) 2019-12-05 2021-06-10 David John O'neill Rapamycin analogs and uses thereof
EP4073102A4 (en) 2019-12-12 2024-05-08 Ting Therapeutics LLC Compositions and methods for the prevention and treatment of hearing loss
CA3163703A1 (en) 2020-01-07 2021-07-15 Steve Kelsey Shp2 inhibitor dosing and methods of treating cancer
EP4139299A1 (en) 2020-04-24 2023-03-01 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
WO2021215545A1 (en) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
US20230255972A1 (en) 2020-07-15 2023-08-17 Taiho Pharmaceutical Co., Ltd. Pyrimidine compound-containing combination to be used in tumor treatment
WO2022060583A1 (en) 2020-09-03 2022-03-24 Revolution Medicines, Inc. Use of sos1 inhibitors to treat malignancies with shp2 mutations
MX2023003060A (es) 2020-09-15 2023-04-05 Revolution Medicines Inc Derivados indolicos como inhibidores de ras en el tratamiento del cancer.
TW202241885A (zh) 2020-12-22 2022-11-01 大陸商上海齊魯銳格醫藥研發有限公司 Ｓｏｓ１抑制劑及其用途
AU2022239614A1 (en) 2021-03-19 2023-10-12 Icahn School Of Medicine At Mount Sinai Compounds for regulating trained immunity, and their methods of use
CN117500811A (zh) 2021-05-05 2024-02-02 锐新医药公司 共价ras抑制剂及其用途
MX2023013084A (es) 2021-05-05 2023-11-17 Revolution Medicines Inc Inhibidores de ras para el tratamiento del cancer.
CN118561952A (zh) 2021-05-05 2024-08-30 锐新医药公司 Ras抑制剂
WO2022250170A1 (en) 2021-05-28 2022-12-01 Taiho Pharmaceutical Co., Ltd. Small molecule inhibitors of kras mutated proteins
WO2023288046A1 (en) 2021-07-15 2023-01-19 President And Fellows Of Harvard College Compositions and methods relating to cells with adhered particles
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
TW202340214A (zh) 2021-12-17 2023-10-16 美商健臻公司 做為shp2抑制劑之吡唑并吡𠯤化合物
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
AU2023275778A1 (en) 2022-05-25 2024-12-12 Revolution Medicines, Inc. Methods of treating cancer with an mtor inhibitor
AU2023285116A1 (en) 2022-06-10 2024-12-19 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024081916A1 (en) 2022-10-14 2024-04-18 Black Diamond Therapeutics, Inc. Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
WO2024167904A1 (en) 2023-02-07 2024-08-15 Arvinas Operations, Inc. Dosage regimens of estrogen receptor degraders in combination with an mtor inhibitor
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
US20240360153A1 (en) 2023-04-07 2024-10-31 Regeneron Pharmaceuticals, Inc. Selective rapamycin analogs and uses thereof
WO2024211663A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
WO2024216048A1 (en) 2023-04-14 2024-10-17 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
WO2024216016A1 (en) 2023-04-14 2024-10-17 Revolution Medicines, Inc. Crystalline forms of a ras inhibitor
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT98990A (pt) * 1990-09-19 1992-08-31 American Home Prod Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
US5221670A (en) * 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
US5120842A (en) * 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5100883A (en) * 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) * 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5118677A (en) * 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US5151413A (en) * 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
CA2086642C (en) 1992-01-09 2004-06-15 Randall E. Morris Method of treating hyperproliferative vascular disease
US5516781A (en) 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
CA2094858C (en) 1992-04-28 2004-06-15 Robert D. Mitchell Method of treating hyperproliferative vascular disease
ZA935112B (en) * 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5256790A (en) * 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
MX9304868A (es) * 1992-08-13 1994-05-31 American Home Prod 27-hidroxirapamicina, derivados de la misma y composicion farmaceutica que la contiene.
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5262423A (en) * 1992-10-29 1993-11-16 American Home Products Corporation Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents
US5258389A (en) * 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US5310903A (en) * 1993-03-05 1994-05-10 Merck & Co., Inc. Imidazolidyl rapamycin derivatives
US5310901A (en) * 1993-03-05 1994-05-10 Merck & Co., Inc. O-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynlheteroarylrapamycin derivatives
US5387680A (en) * 1993-08-10 1995-02-07 American Home Products Corporation C-22 ring stabilized rapamycin derivatives
US5527907A (en) * 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
EP0729471A1 (en) * 1993-11-19 1996-09-04 Abbott Laboratories Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
CZ284650B6 (cs) 1993-12-17 1999-01-13 Novartis Ag Nové demethoxyderiváty rapamycinu, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje

Also Published As

Publication number Publication date
NO975432L (no) 1997-11-26
CN1124276C (zh) 2003-10-15
PT833828E (pt) 2003-02-28
MY145291A (en) 2012-01-13
CA2219659C (en) 2008-03-18
SK168297A3 (en) 1998-05-06
BR9609260A (pt) 1999-05-18
HK1014949A1 (en) 1999-10-08
ES2187660T3 (es) 2003-06-16
MX9709555A (es) 1998-03-31
EP0833828B1 (en) 2002-11-20
AU712193B2 (en) 1999-10-28
KR100400620B1 (ko) 2004-02-18
US5985890A (en) 1999-11-16
RU2158267C2 (ru) 2000-10-27
DE69624921T2 (de) 2003-09-11
IL122212A0 (en) 1998-04-05
NO317058B1 (no) 2004-08-02
HU228234B1 (en) 2013-02-28
PE4598A1 (es) 1998-02-19
HUP9802200A3 (en) 2000-05-29
PL323310A1 (en) 1998-03-16
CN1187821A (zh) 1998-07-15
PL184731B1 (pl) 2002-12-31
TR199701567T1 (xx) 1998-04-21
FI973991A0 (fi) 1997-10-17
CZ392297A3 (cs) 1998-03-18
ATE228135T1 (de) 2002-12-15
US6200985B1 (en) 2001-03-13
CO4440629A1 (es) 1997-05-07
SK284529B6 (sk) 2005-05-05
NZ311647A (en) 1999-11-29
JP2000510815A (ja) 2000-08-22
EP0833828A1 (en) 1998-04-08
NO975432D0 (no) 1997-11-26
FI973991A (fi) 1997-12-09
KR19990022780A (ko) 1999-03-25
FI113051B (fi) 2004-02-27
CA2219659A1 (en) 1996-12-27
JP3226545B2 (ja) 2001-11-05
AR003426A1 (es) 1998-08-05
WO1996041807A1 (en) 1996-12-27
DK0833828T3 (da) 2003-03-17
AU6300696A (en) 1997-01-09
DE69624921D1 (de) 2003-01-02
HUP9802200A2 (hu) 1999-02-01
CZ292233B6 (cs) 2003-08-13
TW410226B (en) 2000-11-01

Similar Documents

Publication Publication Date Title
IL122212A (en) Rapamycin derivatives, pharmaceutical compositions comprising them and their preparation
IL112384A0 (en) Tetracyclic derivatives, their preparation and pharmaceutical compositions containing them
NZ304901A (en) Taxoid derivatives, preparation thereof and pharmaceutical compositions containing same
IL108729A0 (en) Pyrrolo-pyridine derivatives, their preparation and pharmaceutical compositions containing them
HUP9901086A3 (en) Arylsulfonylaminobenzene derivatives, pharmaceutical compositions containing them and their use for producing pharmaceutical compositions
IL125849A (en) Substituted benzenesulfonamide derivatives, their preparation and pharmaceutical compositions comprising them
HUP0001555A3 (en) Tetrahydro-imidazo-naphthyridine derivatives, pharmaceutical compositions thereof and process for their preparation
HUP9802937A3 (en) Benzo[g]quuinoline derivatives, pharmaceutical compositions containing them and their use
IL119559A0 (en) Purin -6- one derivatives their preparation and pharmaceutical compositions containing them
IL119778A (en) Neuropretective pharmaceutical compositions containing rapamycin derivatives
IL125710A0 (en) Arylglycinamide derivatives their preparation and pharmaceutical compositions containing them
HUP0002272A3 (en) Aroyl-piperazine derivatives, their preparation pharmaceutical compositions containing them and their use
HUP9904694A3 (en) Spiropyrrolidine derivatives, their use and pharmaceutical compositions containing them
IL118410A0 (en) Substituted camptothecin derivatives their preparation and pharmaceutical compositions containing them
HUP9602635A2 (en) 4-aciloxy-benzenesulfonamide derivatives, process for their preparation and pharmaceutical compositions containing them
IL108703A0 (en) Substituted azolone derivatives, their preparation and pharmaceutical compositions containing them
ZA967800B (en) Heteroaryllsubstituted acryloylguanidine derivatives and pharmaceutical compositions comprising them
HUP9801386A3 (en) Indazolecarboxamide derivatives, preparation thereof and pharmaceutical compositions containing them
AU5487398A (en) Pyrrole derivatives, their preparation and pharmaceutical compositions containing them
HUP9901485A3 (en) Heterocyclylcarboxamide derivatives, pharmaceutical compositions containing the same, process for their preparation and their use
HUP9602196A2 (en) Sulfonyl- and sulfinyl-benzoyl-guanidine derivatives and pharmaceutical compositions thereof
IL121969A0 (en) 10,13,15-trioxatricyclo[9.2.1.1.9.6]-pentadecanone derivatives their preparation and pharmaceutical compositions containing them
IL116825A0 (en) Vitamin d derivatives their preparation and pharmaceutical compositions containing them
HUP9800631A3 (en) 4-aminotetrahydrobenzisoxazole or -isothiazole derivatives, pharmaceutical compositions containing them and their use for the preparation of pharmaceutical compositions
AU8031598A (en) 3-aminoindane derivatives, process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired